Azoles Used in Agriculture as Possible Cause of Azole-Resistance in Clinical Candida Isolates

Hardeep Kaur¹*, Anamika Yadav¹, Khushbu Wadhwa¹, Kusum Jain¹ and Soma M Ghorai²

¹Department of Zoology, Ramjas College, University of Delhi, Delhi, India.
²Department of Zoology, Hindu College, University of Delhi, Delhi, India.

http://dx.doi.org/10.13005/bbra/2884

(Received: 09 November 2020; accepted: 08 December 2020)

Agricultural azoles are preferred antifungals used by farmers due to their high efficiency against broad range of plant diseases like leaf rust, leaf spots, and powdery mildews. The past few decades have witnessed an unprecedented rise in their usage for crop protection. These compounds can thrive in environment for several months and being fungistatic in nature, can cause imbalance in the ecology of fungal species in the environment. Further their heavy use can lead to contamination and residues in plants, water, soil, and development of human health risk. These azoles share the similar mode of action and structural properties with medical azoles that are used for the treatment of fungal infections. Recent years have also seen an exceptional surge in the number of multi-drug resistant nosocomial Candida infections, especially in immuno compromised patients. The present review is an attempt to show the plausible mechanism of cross resistance among Candida isolates to agricultural and medical azoles. The study highlights the requirement of thorough scrutiny of usage of azoles both in medicine and agriculture.

Keywords: Amphotericin; Cross-resistance; Echinocandin; Fluconazole.

Soil is a dynamic entity and a good platform for the exchange of matter and energy. It provides the main niche for all kinds of microorganisms including fungi (90% of biomass of soil is composed of bacteria and fungi)¹. Mycotoxins produced by some fungi like Fusarium not only spoil farm yield but also harm the consumers. Hence, fungicides are used in crop plants to prevent harvest losses. The last five decades has heralded the introduction of azoles as a popular fungicide in agriculture and as antifungicides in clinics². Lately, it has been observed that overuse of azoles as fungicides in agriculture can lead to cross-resistance among various fungal species and is an important reason for emergence of novel resistant fungi such as Candida auris in clinical samples³.

Human fungal infections generally do not receive much attention as compared to bacterial and viral diseases; however, mortality rate from invasive fungal infections is increasing exponentially despite the use of antifungal drugs⁴. Among the common fungal infections afflicting human, Candidiasis due to the yeast Candida affects millions of people annually. Mainly associated with hospitalization, the infection usually has a predilection for immunocompromised individuals⁵. It has been reflected as the predominant systemic...
infection causing pathogen in patients with COPD, AIDS, and cancer. Most importantly, the resistant isolates of Candida have the potential to form biofilms. The thick polymeric extracellular layer protects Candida aggregates as it forms a tough barrier against known antimicrobial substances.

The emergence of clinical Candida isolates exhibiting multi drug resistance (MDR) has further alarmed microbiologists. The usual Candida species predominantly found in clinics are susceptible to amphotericin B, azoles, and echinocandins, but certain novel emerging fungal species have demonstrated resistance to all the three primary antifungal drugs. Ironically, amphotericin B performs slightly better whereas azoles are confirmed to be the least effective against such species. Though in most clinical isolates, resistance to antifungal is due to long term azole therapy, wherein the fungus was adapting rapidly to the azole drug being used; however it was also seen that certain patients who were never exposed to azole drugs, showed resistance. Such incidences are a wakeup call and indicate that these patients perhaps are coming in contact with azole resistant fungal strains present in the environment.

Candida species in patients and environment
Candida is an important opportunistic fungal pathogen that causes disease in immuno compromised patients and is also present in the environment. It causes infections in mouth, skin, and vagina along with invasive bloodstream infections. Candida albicans is the major causal agent of all forms of candidiasis. However, the pattern has changed in the last decade with majority of the non albicans Candida species (NACS) getting associated with the nosocomial invasive infections. Candida glabrata, Candida parapsilosis and Candida tropicalis are the important pathogens in this category. Higher mortality rate in patients with C. glabrata over C. albicans is due to the fact that it can survive during long term starvation conditions upon phagocytosis by macrophages, as well as low pH environment in vagina or in phagolysosomes. C. glabrata thus is associated with the enormous adaptability to survive in different host niches. C. tropicalis is a diploid dimorphic fungal pathogen which causes infections mainly in patients with neutropenia and hematological malignancies. Similarly, C. parapsilosis is also a diploid dimorphic fungus which mainly affects the immuno compromised individuals and can cause major health risk to neonates with low birth weight.

Almost ubiquitously, many Candida species are found in every kind of managed soil (Table 1); though variation depends on the type of soil, climatic condition and water abundance. Fungi ferment and assimilate different types of sugars provided by the plants to soil e.g. C. auris ferment glucose, sucrose but assimilate maltose, mannitol, sorbitol as carbon sources. The abundance of different sugars in different soil decides the variation in fungal community which further gets enhanced due to regular tillage and mixing of upper layer of soil.

Use ofazole in agriculture and medicine
Fungal diseases in plants cause a massive loss in crop yield worldwide. In agriculture, fungicides are mainly used to control the fungal growth on plants and also to arrest post-harvest spoilage of agricultural product. Before 1970s, many compounds such as dithiocarbamate, benzimidazoles, were predominantly used as antifungal agents of all forms of candidiasis; though in later times, azoles gained prominence due to their site-specific inhibitory action which made them much more beneficial. However the strength and efficacy of different azole derivatives against fungal pathogen is highly variable. Despite that, the usage of azole-based fungicide has increased from 100 tons to 145 tons i.e. 45% in 4 years in Taiwan (2005 to 2009). Throughout the world, fungicide share 27% of anti-pest chemicals and this number is 15% in India; which is rising exponentially to the demand of increasing population. Certain features of azoles make them preferred fungicides among farmers e.g. they possess long–lasting stability and high efficacy against broad range of plant pathogens. The azole fungicides are selective only for fungal species and target their ergosterol biosynthetic pathways. They also show very low toxicity for both the farmers who apply them and the plants that are under treatment, as both plant and animal cells do not contain ergosterol in their plasma membrane which is an important component of fungal cell membrane. Therefore, the massive use of azoles in agriculture exerts a strong selective pressure on the pathogenic fungi to survive in environment.
On the other hand, in medicine, the increase in prophylactic usage of therapeutic azoles has led to surge in the cases of resistant fungal isolates. Previously *C. albicans* was considered as a ubiquitous fungus in hospitals and cause of nosocomial infections\(^\text{26,27,28}\); but nowadays, other species have also paved their way to the hospital wards. These non-*albicans* Candida species (NACS) are distributed according to geographic areas e.g., *C. tropicalis* majorly found in Asia, in organic soil near waterbodies\(^\text{29,30,31}\) while *C. glabrata* predominate in western countries\(^\text{32, 33}\).

The similar mode of action of azoles used in agriculture and medicine perhaps has led to cross-resistance along with increased presence of resistant fungal strains in environment and in clinics.

**Correlation between the use of azoles in agriculture and development of resistance in clinical fungi**

Bacteria and fungi in soil develop antibiotic and antifungal resistance mechanism as a natural process. Nevertheless, the mechanism of resistance in fungi and its transmission differs significantly from that in bacteria. There is no evidence that genes that confers resistance in fungi are transferred horizontally, a major difference from bacteria\(^\text{34}\). Acquired resistance is less common than intrinsic resistance in fungi because they do not exchange the resistance genes via plasmids, therefore selection of resistance mechanisms in fungi occur as an outcome of the antifungal use\(^\text{35}\). Most of the pathogenic fungi have their natural habitat in the environment and spores of fungi generally spread over long distance by air flow. Many fungal pathogens are present in both environment and clinics e.g. *Aspergillus fumigatus*, a saprophytic fungi that survive on decaying organic substances like leaves, fruits, etc. These fungi produce spores that are blown off by air and spread to other organisms e.g. humans. These spores mainly cause *Aspergillosis* in humans. As inhalation is the main route of these spores, so if an azole-resistant *A. fumigatus* is present in human surroundings then this resistant strain can enter the human body and can lead to the development of azole-resistant fungal disease\(^\text{36}\). Not with standing, compost present in gardens and in indoor plants could also act as an ecological niche for the various spores of fungi as well as azole residues; and can play an important role in development of azole resistance\(^\text{36}\).

Clinical azole drugs represent the major core therapy for treating fungal diseases in human\(^\text{35}\). Normally, treatment of the patients over longer period of time with antifungals can result in the selection of resistant strains. However it has been seen that exposure of fungi to azoles in agricultural field develops cross resistance to medical triazoles\(^\text{37}\). Due to the presence of genetic homology between the clinical and agricultural isolates, it has been suggested that environment is the most common route for the emergence of azole resistant isolates in clinics and hospitals. In a study, it was found out that 50% of *C. tropicalis* strains isolated from the soil are 97% identical to those of human\(^*\) *C. tropicalis* while 33.3% are completely identical (100%) to human\(^*\) *C. tropicalis*. It was also seen that *C. tropicalis* isolated from humans and soil with reduced susceptibility to fluconazole are showing reduced susceptibility to other azoles that are in continuous use in agriculture\(^\text{31}\).

Even though development of resistance is a complex process and takes time to achieve, extensive data has revealed that azoles exert a strong selective pressure over fungal population to choose resistant strains e.g. Benzimidazole when initially introduced was a revolutionary agent against pathogen but later on some strains of the pathogen which are naturally resistant to benzimidazole got selected naturally and emerged further\(^\text{38}\). This forms a major concern for microbiologists nowadays. Strains of fungi, isolated from HIV patients, pre-treated with azoles are found to be resistant to fluconazole and they also show cross-resistance to azoles used in agriculture, with high minimum inhibitory concentration (MIC) values. Resistance to medically important antifungals imposes a big challenge to clinicians in treating invasive fungal diseases. The knowledge about the rate and extent of development of resistance mechanism in the fungi and whether the mutation associated with this resistance is reversible or not is a very important point in the clinical medicine. The resistance to variety of antifungal depends on many factors for instance, the pharmacokinetic and pharmacodynamics properties of the drug, the target site of the drug and its mode of action in organism. It has been studied that there are mainly three ways by which patients may acquire the azole
resistant fungi (1) initially, the infecting strain of fungi is susceptible to antifungal but as it mutates it develops azole resistance, (2) the individual may harbor the heterogeneous population of infecting strain due to which resistant strain get selected during antifungal treatment over a period of time, or (3) the individual may acquire resistant strain from the external milieu.

**Mode of action of azole antifungals in Candida spp.**

Binding of azoles gets impaired by genetic alteration in ERG11 gene which mainly accounts for more than 90% of azole resistance in clinical isolates. The ERG11 gene encodes the enzyme cytochrome P450 14α-demethylase (also called lanosterol 14α-demethylase) which is the primary

Table 1. *Candida* species isolated from different kinds of managed soil

| *Candida* species present | Type of managed soil | References |
|--------------------------|----------------------|------------|
| *Candida glabrata*       | Vineyard             | 18         |
| *Candida parapsilosis*   | Agricultural         | 19         |
| *Candida apis*           | Pasture              | 20         |
| *Candida azyma*          | Rhizosphere          | 21         |
| *Candida diddensiae*     | Rhizosphere          | 21         |
| *Candida sake*           | Agricultural         | 22         |
| *Candida (Torulopsis) magnolia* | Agricultural     | 19         |

Fig. 1. Action of azoles in Ergosterol biosynthetic pathway
target for the azole compounds. Azole compounds are classified into two types depending on the number of nitrogen atom present in it. Imidazoles (miconazole, ketoconazole) contain two nitrogen atoms in the ring; while triazoles (fluconazole, itraconazole, posaconazole, voriconazole) have three nitrogen atoms in ring. The nitrogen atom plays an important role in the action mechanism of azoles as it bind to the heme group of the enzyme encoded by the gene. The enzyme encoded by the ERG11 plays a major role in removing the methyl group from lanosterol and then converting it into ergosterol. The ergosterol is a major component of the plasma membrane of fungi; hence it has a major role in maintaining the integrity of the cell membrane and also participates in the cell signaling pathways. The azole compounds work by inhibiting the function of lanosterol 14α-demethylase enzyme which will result in the accumulation of the methylated toxic precursors (Fig. 1). The build-up of these precursors in the cell makes plasma membrane leaky and impairs the fungal growth.

**Mechanism of azole resistance in Candida spp.**

Resistance to azole antifungals in Candida spp. has been extensively studied. In *C. albicans* azole resistance can be broadly attributed to (i) overexpression of ABC and MDR1 efflux pumps (ii) enhanced production of 14α-lanosterol demethylase via ERG11 gene up-regulation; (iii) decreased affinity of azole drugs due to point mutations in ERG11 gene and (iv) homozygous ERG3 deletion mutation leading to the loss of sterol 5,6-desaturase activity. These mechanisms are elucidated as follows:

---

**Over expression of efflux pump**

Mutations in trans-regulatory factors culminate into up-regulation of genes encoding for efflux pumps and are the major cause for drug-resistance in *C. albicans* isolates (Fig. 2). ATP-binding cassette (ABC) is the primary active transporter of the cell membrane having four domains- two Nucleotide-binding domain (NBD1 and NBD2) that binds to ATP and hydrolyze it to let the solute out of the cell and the other two domains are the transmembrane domain (TMD1 and TMD2). For azole resistance in *C. albicans*, mainly ABC transporter comes in focus as out of two ABC transporters CDR1 and CDR2, CDR1 plays a major role and gets upregulated. In *C. auris*, along with CDR1 and CDR2, another ABC
transporter Snq2 plays a role in azole resistance. Various transcriptomic studies have concluded that efflux pump's overexpression along with some zinc cluster transcriptional factors e.g. TAC1 (transcriptional activator of CDR genes) are the main cause of azole resistance. Exposure to fluconazole, cause mutations in TAC1B which is located near the mating type locus, as the major regulator of CDR1 and CDR; and these mutations were found in many isolates of fluconazole-resistant *C. auris*.45

Over expression of another efflux pump, MDR1 has also been found to be responsible for drug resistance in *C. albicans* isolates. Genetic alterations in MRR1 (multi drug resistance regulator 1), a zinc cluster transcription factor is the major factor for MDR1 over expression and multi drug resistance. Mrr1p target genes encode oxidoreductases and it has been suggested that *MRR1* gain-of-function mutations may be in response to the oxidative damage of the cells due to azoles, and the up regulation of Mrr1p target genes may play a role to restore the intracellular redox balance; thereby causing resistance.46

**Increased expression of ERG11 gene and enhanced ergosterol synthesis**

Expression of a target enzyme is also up-regulated in cell by increased transcription rate of a gene; by gene amplification; and by decreased degradation of the gene product. Additionally, transcriptional factors may play a major role in expression of gene and susceptibility towards azole drug. The Upc2p is a zinc finger transcription factor and acts as a key regulator that regulates the expression of genes involved in ergosterol biosynthesis, including ERG11 gene.47 In *C. albicans*, a gain of function mutation of Upc2p may lead to the increased production of the ergosterol, hence leading to resistance to fluconazole whereas, disruption of Upc2p results in enhanced fluconazole (FLC) activity. It was hence observed that Upc2p affects the azole susceptibility via ergosterol biosynthesis.48 49

**Point mutations in ERG11 gene and amino acid substitution**

The point mutations (insertion and deletion) in the ERG11 gene leads to the reduced binding of the azole drug and results in the origin of the clinically resistant isolates (Fig. 3). Mechanism of resistance is mostly studied in *C. albicans*. Many amino acid substitutions have been found in the ERG11 gene product but only a few are experimentally confirmed to have a link with azole resistance.50 Usually, amino acid substitution that occurs in the hot spot regions of 105-165, 266-287, 405-488 bp in Erg11p are the ones that lead to azole resistance.48 The molecular analysis has revealed that these substitutions occur in the catalytic site of the enzyme due to which there is a decrease in binding affinity of drugs.44 51

For *C. auris*, some specific substitution is in focus e.g. in South American and South Asian clade of *C. auris*, K143R and Y132F substitution takes place, while in African clade, F126L substitution is most common.52 In the case of *C. glabrata* such substitutions were not found and only a single case of this kind of resistance mechanism was found in *C. glabrata*.51

**Alteration of ergosterol biosynthetic pathway by inactivation of ERG-3 gene**

Fungi is found in different kinds of environmental niches and is accompanied by diverse environmental stress.53 For fungi, antifungals are also a kind of stress to which they adapt and try to survive.54 The main mechanism of resistance for *C. albicans* is the remodeling of the ergosterol biosynthesis pathway. This occurs as a result of the loss of function mutation in ERG-3 gene. ERG-3 gene is responsible for coding sterol Δ-5,6 desaturase and because of loss of function mutation, deactivation of this enzyme occurs due to which there is no accumulation of methylated sterols formed due to azole action on the fungal membrane.55 As a result there will be less loss of fungal cell by azoles i.e. decreased susceptibility of fungi to azoles. In *C. albicans* there is five missense mutations and two non-sense mutations, which are responsible for the loss of function and resistance to azoles.50 56

As true for stress response in every organism, chaperone, such as Hsp90, works well in the fungal cell also. Hsp90 is a protein folding molecule and is considered as the main molecule involved in developing resistance in *C. albicans*. Alternatively, it was also observed that a very high amount of doxycycline is required to inhibit Hsp90 function in *C. auris* than *C. albicans*.57 Hence, in *C. auris*, azole resistance arises due to increase in the function of efflux pump and is observed to be independent of Hsp90.57 58
Besides the above important mechanisms, aneuploidy has also been found to play a role in azole resistance in *Candida*. Aneuploidy leads to genetic diversity by allelic imbalances and loss of heterozygosity (LOH) at any of parental allele. In fungal pathogen, this aneuploidy and LOH results in a change of working pattern of efflux pump and change in action site of the drug; and these factors together lead to resistance in fungi. Usually, a fungal cell has a good genetic diversity which results in phenotypic plasticity and ultimately resistance. In *C. albicans*, by the different combination of hybridization, it was found out that aneuploidy occurs on chromosome 1, 2, 5 which usually contributes to the resistance initiation\(^{59,60}\). This LOH often leads to the gain of function mutation for the efflux pump and other drug targets resulting in resistance. In *C. albicans* aneuploidy on chromosome 5 is more common and this resistance is linked to a high copy number of ERG11 and TAC1 genes\(^{60,61}\).

**Modes of transmission of resistant fungi**

Air can be a possible source for transmission of fungi from field to hospital especially the transmission of those fungi that sporulate e.g. *A. fumigatus*. Insects (especially insects belonging to Muscidae, Calliphoridae class) can also act as vectors for resistant fungal strains\(^{62,63,64}\). Direct contact of farmers and workers during field management and post-harvest processing may also transfer fungi from fields to human. Raw fruits and vegetables are considered as a good source of nutrients and part of good healthy diet but food contaminating fungi have become a point of concern because of their increasing resistance to antifungals. There is an increasing demand for these fresh raw fruits and vegetables that led to 25% increase in consumption of fruits from 1977-1979 to 1997-1999 in the USA\(^{65}\). This had prompted some industries to conduct risk analysis and management practice for these fresh produces but still, there are increasing number of diseases associated with fruit-consumption\(^{66}\). Researchers working in this field face the major challenge of lack of information among affected patients on the source of contamination and procurement of the raw fruits and vegetables consumed\(^{67}\). As all of these products belong to the food supply chain in which farmers provide these resources to the wholesale market; and from these markets different distribution agencies procure goods; so ultimately no one knows the real source of the contaminated or even infected fruits and vegetables. In 1995, there was a simultaneous breakout of *Salmonella* Stanley due to usage of alfalfa sprouts in the USA and Finland; which was finally traced down to a common source of contaminated seeds shipped by a merchant\(^{68}\). In different studies, it was found out that raw fruits and vegetables are also a good source for microbial transmission from fields to human. In a study, nearly 184 yeasts were isolated from fruits that had a high percentage of *Candida* species responsible for causing diseases in human and all of these species showed decreased susceptibility to fluconazole (MIC ≥8mg/ml)\(^{24}\). Another study conducted in 14 countries over a population of 883 million; showed that nearly 2% population in every country is infected with fungal infection\(^{69}\). These results hence suggest that the path for transmission of resistant fungi is indeed from the fields to human.

Different agencies and institutes e.g. Food and drug administration (FDA), European medicines agency (EMA) regulate the usage of antifungal in fields\(^{70}\). CLSI (Clinical and Laboratory Standards Institute) and EUCAST (European Committee on Antimicrobial Susceptibility Testing) have provided protocol to check the susceptibility of different fungi for different drugs\(^3\). But there is no such committee to check and regulate the usage of azoles in different fields in India. Hence there is an urgent need to make guidelines for usage of azoles in agriculture that could break this chain of transmission of resistant fungal strains from fields to human.

**CONCLUSION**

The fungal strains that are resistant to azoles have a great impact on human health. They generally acquire the resistance mechanism in the form of efflux pumps that lowers the concentration of a drug inside the cell or by other genetic modifications that decreases the susceptibility to drugs. The increase in azole resistance eventually leads to increase in virulence of such strains. Infections caused by these resistant isolates are more difficult to control by host defense mechanisms. Development of resistance to antifungal drugs generally leads to treatment failure in patients. However therapeutic failure in
patients is dependent on many factors like immune status of host, site and severity of infection, drug interaction with target site, dosage of drug, cellular organization of the fungi, hyphal morphology, serotype, biofilm production and fungal load. Research in this field should focus on to establish the inter-linkages between the mutant fungal strains, their resistance to agricultural azoles and eventual cross resistance to medical triazoles. However, even if relationship between the use of azole compounds and development of resistance in Candida is proven, further control of its spread and development of resistant isolates is almost impossible to curtail as they are already present in environment. The only limiting factor should be the judicial use of fungicides in horticulture and agriculture and stringent regulatory practices and surveillance for clinical testing of cultures of fungal isolates in human patients.

REFERENCES

1. Nielsen M.N., Winding A. Microorganisms as indicators of soil health. National Environmental Research Institute. NERI Technical Report No. 388, Denmark 2002.
2. Russel P.E. A century of fungicide evolution. *Journal of Agricultural Science* 2005; 143:11–25.
3. Ribas E., Ribas A.D., Spolti P., Del Ponte E.M., Donato K.Z., Schrekker H., Fuenteeria A.M.Is the emergence of fungal resistance to medical triazoles related to their use in the agroecosystems? A mini review. Brazilian journal of microbiology: publication of the *Brazilian Society for Microbiology* 2016; 47(4): 793–799.
4. Fisher M.C., Henk D.A., Briggs C.J., Brownstein J.S., Madoff L.C., McCraw S.L., Gurr S.J. Emerging fungal threats to animal, plant and ecosystem health. *Nature* 2012; 484(7393): 186-194.
5. VandeputteP., Ferrari S., Coste A.T. Antifungal resistance and new strategies to control fungal infections. *International journal of microbiology* 2012; 713687.
6. Marr K.A., Carter R.A., Boechk M., Martin P., Corey L. Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. *Blood* 2002; 100(13): 4358-4366.
7. Guinea J., Torres-Narbona M., Gijón P., Muñoz P., Pozo F., Peláez T., de Miguel J., Bouza, E. Pulmonary aspergillosis in patients with chronic obstructive pulmonary disease: incidence, risk factors, and outcome. *Clinical microbiology and infection: the official publication of the European Society of Clinical Microbiology and Infectious Diseases* 2010; 16(7): 870–877.
8. Brown G.D., Denning D.W., Gow N.A., Levitz S.M., Netea M.G., White T.C. Hidden killers: human fungal infections. *Science translational medicine* 2012; 4(165): 165rv13.
9. Armstrong-James D., Meintjes G., Brown G.D. A neglected epidemic: fungal infections in HIV/AIDS. *Trends in microbiology* 2014; 22(3), 120–127.
10. Denning D.W. Minimizing fungal disease deaths will allow the UNAIDS target of reducing annual AIDS deaths below 500 000 by 2020 to be realized. *Philosophical transactions of the Royal Society of London. Series B, Biological Sciences* 2016; 371(1709): 20150468.
11. Limper A.H., Adenis A., Le T., Harrison T.S. Fungal infections in HIV/AIDS. *The Lancet. Infectious diseases* 2017; 17(11): e334–e343.
12. Cavalheiro M., Teixeira M.C. Candida Biofilms: Threats, Challenges, and Promising strategies. *Front Med (Lausanne)* 2018; 5:28.
13. Richtel M., Jacobs A.A. Mysterious Infection, Spanning the Globe in a Climate of Secrecy. New York Times. from https://www.nytimes.com/2019/04/06/health/drug-resistant-candida-aureus.html.2019.
14. Kaufmann C.A., Marr K.A., Thorner A.R. Management of candidemia and invasive candidiasis in adults. *UpToDate*. from https://www.uptodate.com/contents/management-of-candidemia-and-invasive-candidiasis-in-adults. 2019.
15. Whaley S.G., Berkow E.L., Rybak J.M., Nishimoto A.T., Barker K.S., Rogers P.D. Azole antifungal resistance in Candida albicans and emerging non-albicans Candida species. *Frontiers in microbiology* 2017; 7: 2173.
16. OseiSekyere J. Candida auris: A systematic review and meta-analysis of current updates on an emerging multidrug-resistant pathogen. *MicrobiologyOpen* 2018; 7(4): e00578.
17. Lone S.A., Ahmad A. Candida auris-the growing menace to global health. *Mycoses* 2019; 62(8): 620–637.
18. Kachalkin A.V., Abdullabekova D.A., Magomedova E.S., Magomedov G.G., Chernov I.Y. Yeasts of the Vineyards in Dagestan and Other Regions. *Mikrobiologija* 2015; 84(3): 360-368.
19. Lund A. Studies on the ecology of yeasts. *Munksgaard, Copenhagen*.1954.
20. Parle J.N., Di Menna M.E., The source of yeasts in New Zealand wines. *New Zealand Journal of
11. Warnock D.W. Trends in the epidemiology of amphotericin B and fluconazole of yeast species and susceptibility testing of a 10-year collection of Candida spp. isolated from patients with candidemia. *Journal of chemotherapy (Florence, Italy)* 2011; **23**(2): 92–96.

12. Warnock D.W. Trends in the epidemiology of invasive fungal infections. *Nihon IshinkinGakkaizasshi. Japanese journal of medical mycology* 2007; **48**(1): 1–12.

13. Yang Y.L., Ho Y.A., Cheng H.H., Ho M., Lo H.J. Susceptibilities of Candida species to amphotericin B and fluconazole: the emergence of fluconazole resistance in Candida tropicalis. *Infection control and hospital epidemiology* 2004; **25**(1): 60–64.

14. Chai L.Y., Denning D.W., Warn P. Candida tropicalis in human disease. *Critical reviews in microbiology* 2010; **36**(4): 282–298.

15. Yang Y.L., Cheng M.F., Wang C.W., Wang A.H., Cheng W.T., Lo H.J., Tsary Hospitals. The distribution of species and susceptibility of amphotericin B and fluconazole of yeast pathogens isolated from sterile sites in Taiwan. *Medical Mycology* 2010; **48**(2): 328–334.

16. Yang Y.L., Lin C.C., Chang T.P., Lauderdale T.L., Chen H.T., Lee C.F., Hsieh C.W., Chen P.C., Lo H.J. Comparison of human and soil Candida tropicalis isolates with reduced susceptibility to fluconazole. *PLOS One* 2012; **7**(4): e34609.

17. Pfäffler M.A., Moet G.J., Messer S.A., Jones R.N., Castanheira M. Geographic variations in species distribution and echinocandin and azole antifungal resistance rates among Candida bloodstream infection isolates: report from the SENTRY Antimicrobial Surveillance Program (2008 to 2009). *Journal of clinical microbiology* 2011; **49**(1): 396–399.

18. Azevedo M.M., Faria-Ramos I., Cruz L.C., Pina-Vaz C., Goncalves Rodrigues A. Genes of azole antifungal resistance from agriculture to clinical settings. *Journal of agricultural and food chemistry* 2015; **63**(34): 7463–7468.

19. Arendrup M.C. Update on antifungal resistance in Aspergillus and Candida. *Clinical microbiology and infection* 2014; **20**: 42–48.

20. Snelders E., Rijs A.J., Kema G.H., Melchers W.J., Verweij P.E. Possible environmental origin of resistance of Aspergillus fumigatus to medical triazoles. *Appl. Environ. Microbiology* 2009; **75**(12): 4053–4057.

21. Verweij P.E., Snelders E., Kema G.H., Mellado E., Melchers W.J. Azole resistance in Aspergillus fumigatus: a side-effect of environmental fungicide use? *The Lancet infectious diseases* 2009; **9**(12): 789–795.

22. Chowdhary A., Kathuria S., Xu J., Meis J.F. Emergence of azole-resistant Aspergillus fumigatus strains due to agricultural azole use creates an increasing threat to human health. *PLoS pathogens* 2013; **9**(11).

23. Russell P. Fungicide resistance: Occurrence and management. *The Journal of Agricultural Science* 1995; **124**(3): 317–323.

24. Perea S., López-Ribot J.L., Wickes B.L., Kirkpatrick W.R., Dib O.P., Bachmann S.P., Keller S.M., Martinez M., Patterson T.F. Molecular mechanisms of fluconazole resistance in Candida dubliniensis isolates from human immunodeficiency virus-infected patients with oropharyngeal candidiasis. *Antimicrobial Agents and Chemotherapy* 2002; **46**(6): 1695–703.

25. Marichal P., Koymans L., Willemsens S., Bellens D., Verhasselt P., Luyten W., Borgers M., Ramaekers F., Odds F.C., VandenBossche H. Contribution of mutations in the cytochrome P450 14alpha-demethylase (Erg1lp, Cyp51lp) to azole resistance in Candida albicans. *Microbiology (Reading, England)* 1999; **145** (Pt 10): 2701–2713.

26. White T.C., Marr K.A., Bowden R.A. Clinical, cellular, and molecular factors that contribute to antifungal drug resistance. *Clinical microbiology reviews* 1998; **11**(2): 382–402.

27. Coleman J.J., Mylonakis E. Efflux in fungi: la pièce de résistance. *PLOS pathogens* 2009; **5**(6): e1000486.
review of microbiology 2017; 71: 753–775.

44. Revie N.M., Iyer K.R., Robbins N., Cowen L.E. Antifungal drug resistance: evolution, mechanisms and impact. Current opinion in microbiology 2018; 45: 70–76.

45. Rybak J.M., Muñoz J.F., Barker K.S., Parker J.E., Esquivel B.D., Berkow E.L., Lockhart S.R., Gade L., Palmer G.E., White T.C., Kelly S.L., Cuomo C.A., Rogers P.D. Mutations in TAC1B: a Novel Genetic Determinant of Clinical Fluconazole Resistance in Candida auris. mBio 2020; 11(3): e00365-20.

46. Morschhäuser J., Barker K.S., Liu T.T., Bla-B-Warmuth J., Homayouni R., Rodgers P.D. The transcription factor MtrR controls expression of the MDR1 efflux pump and mediates multidrug resistance in Candida albicans. PLoS Pathog 2007; 3(11):e164.

47. Vásicek E.M., Berkow E.L., Flowers S.A., Barker K.S., Rogers P.D. UPC2 is universally essential for azole antifungal resistance in Candida albicans. Eukaryotic cell 2014; 13(7): 933–946.

48. Tobadic S., Kratzer C., Presterl E. Azole resistant Candida spp.–emerging pathogens? Mycoses 2012; 55: 24–32.

49. Flowers S.A., Barker K.S., Berkow E.L., Toner G., Chadwick S.G., Gygax S.E., Morschhäuser J., Rogers P.D. Gain-of-function mutations in UPC2 are a frequent cause of ERG11 upregulation in azole-resistant clinical isolates of Candida albicans. Eukaryotic cell 2012; 11(10): 1289–1299.

50. Morio F., Pagniez F., Lacroix C., Miegeville M., Le Pape P. Amino acid substitutions in the Candida albicans sterol $\Delta5,6$-desaturase (Erg3p) confer azole resistance: characterization of two novel mutants with impaired virulence. The Journal of antifungal chemotherapy 2012; 67(9): 2131–2138.

51. Hull C.M., Parker J.E., Bader O., Weig M., Gross U., Warrilow A.G., Kelly D.E., Kelly S.L. Facultative sterol uptake in an ergosterol-deficient clinical isolate of Candida glabrata harboring a missense mutation in ERG11 and exhibiting cross-resistance to azoles and amphotericin B. Antimicrobial agents and chemotherapy 2012; 56(8): 4223–4232.

52. Lockhart S.R., Etienne K.A., Vallabhaneni S., Farooqi J., Chowdhary A., Govender N.P., Colombo A.L., Calvo B., Cuomo C.A., Desjardins C.A., Berkow E.L., Castanheira M., Magobo R.E., Jabeen K., Ashgar R.J., Meis J.F., Jackson B., Chiller T., Litvinseva A.P. Simultaneous Emergence of Multidrug-Resistant Candida auris on 3 Continents Confirmed by Whole-Genome Sequencing and Epidemiological Analyses. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America 2017; 64(2):134–140.

53. Lee Y., Puimala E., Robbins N., Cowen L.E. Antifungal Drug Resistance: Molecular Mechanisms in Candida albicans and beyond. Chemical reviews 2020; 10.1021/acs.chemrev.0c0199. 2020.

54. Cowen L.E., Lindquist S. Hsp90 potentiates the rapid evolution of new traits: drug resistance in diverse fungi. Science (New York, N.Y.) 2005; 309(5744): 2185–2189.

55. Kelly S.L., Lamb D.C., Kelly D.E., Manning N.J., Loeffler J., Hebart H., Schumacher U., Einsele H. Resistance to fluconazole and cross-resistance to amphotericin B in Candida albicans from AIDS patients caused by defective sterol delta5,6-desaturation. FEBS Letters 1997; 400(1): 80–82.

56. Spettel K., Baroucas W., Makristathis A., Zeller I., Mehr N., Selitsch B., Lackner M., Rath P.M., Steinmann J., Willinger B. Analysis of antifungal resistance genes in Candida albicans and Candida glabrata using next-generation sequencing. PLOS One 2019; 14(1): e0210397.

57. Kim S.H., Iyer K.R., Pardeshi L., Muñoz J.F., Robbins N., Cuomo C.A., Wong K.H., Cowen L. E. Genetic Analysis of Candida auris Implicates Hsp90 in Morphogenesis and Azole Tolerance and Cdr1 in Azole Resistance. mBio 2019; 10(1): e02529-18.

58. Cowen L.E., Steinbach W.J. Stress, drugs, and evolution: the role of cellular signaling in fungal drug resistance. Eukaryotic cell 2008; 7(5): 747–764.

59. Selmecki A., Bergmann S., Berman J. Comparative genome hybridization reveals widespread aneuploidy in Candida albicans laboratory strains. Molecular Microbiology 2005; 55(5): 1553–1565.

60. Selmecki A., Forche A., Berman J. Aneuploidy and isochromosome formation in drug-resistant Candida albicans. Science (New York, N.Y.) 2006; 313(5785): 367–370.

61. Coste A., Selmecki A., Forche A., Diogo D., Bougnoux M.E., d’Enfert C., Berman J., Sanglard D. Genotypic evolution of azole resistance mechanisms in sequential Candida albicans isolates. Eukaryotic cell 2007; 6(10): 1899–1904.

62. Iwasa M., Makino S., Asakura H., Kobori H., Morimoto Y. Detection of Escherichia coli O157: H7 from Muscadomestica (Diptera: Muscidae) at a cattle farm in Japan. Journal of medical entomology 1999; 36(1): 108–112.

63. Talley J.L., Wayadande A.C., Wasala L.P., Gerry A.C., Fletcher J., DeSilva U., Gilliland
S.E. Association of Escherichia coli O157: H7 with filth flies (Muscidae and Calliphoridae) captured in leafy greens fields and experimental transmission of E. coli O157: H7 to spinach leaves by house flies (Diptera: Muscidae). *Journal of food protection* 2009; 72(7): 1547–1552.

64. Sela S., Nestel D., Pinto R., Nemny-Lavy E., Bar-Joseph M. Mediterranean fruit fly as a potential vector of bacterial pathogens. *Applied and environmental microbiology*, 2005; 71(7): 4052–4056.

65. Pollack S. Consumer Demand for Fruit and Vegetables: The U.S. Example: Economic Research Service. Washington, DC, USA: United States Department of Agriculture. 2001

66. Sivapalasingam S., Friedman C.R., Cohen L., Tauxe R.V. Fresh produce: a growing cause of outbreaks of foodborne illness in the United States, 1973 through 1997. *Journal of food protection* 2004; 67(10): 2342–2353.

67. Berger C.N., Sodha S.V., Shaw R.K., Griffin P.M., Pink D., Hand P., Frankel G. Fresh fruit and vegetables as vehicles for the transmission of human pathogens. *Environmental Microbiology* 2010; 12(9): 2385–2397.

68. Mahon B.E., Pönkä A., Hall W.N., Komatsu K., Dietrich S.E., Siitonen A., Cage G., Hayes P.S., Lambert-Fair M.A., Bean N.H., Griffin P.M., Slutsker L. An international outbreak of Salmonella infections caused by alfalfa sprouts grown from contaminated seeds. *The Journal of infectious diseases* 1997; 175(4): 876–882.

69. Denning D.W. Calling upon all public health mycologists: To accompany the country burden papers from 14 countries. *European journal of clinical microbiology and infectious diseases: official publication of the European Society of Clinical Microbiology*, 2017; 36(6): 923–924.

70. Aparicio J.F., Mendes M.V., Antón N., Recio E., Martin J.F. Polyene macrolide antibiotic biosynthesis. *Current medicinal chemistry* 2004; 11(12): 1645–1656.